Core Products include Kineret within the Inflammation therapeutic area and Orfadin, Ammonaps and Ammonul within the Genetics and Metabolic therapeutic area.
Kineret and Orfadin are Sobi’s two largest products in terms of revenue. In 2012, these two products accounted for close to 40% of the company’s total revenues and approximately 90% of total revenues for Core Products.
Revenues by Core Product
